Ardelyx/$ARDX
1D1W1MYTD1Y5YMAX
About Ardelyx
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. Its products Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.
- Ticker
- $ARDX
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 489
- Headquarters
- Waltham, United States
- Website
- www.ardelyx.com
Ardelyx Metrics
BasicAdvanced
$1B
-
-$0.23
-
-
Price and volume
Market cap
$1B
52-week high
$8.40
52-week low
$3.86
Average daily volume
4.1M
Financial strength
Current ratio
3.342
Quick ratio
2.891
Long term debt to equity
188.549
Total debt to equity
189.585
Interest coverage (TTM)
-1.24%
Profitability
EBITDA (TTM)
-32.106
Gross margin (TTM)
75.02%
Net profit margin (TTM)
-12.35%
Operating margin (TTM)
-7.86%
Effective tax rate (TTM)
-0.41%
Revenue per employee (TTM)
$920,000
Management effectiveness
Return on assets (TTM)
-4.25%
Return on equity (TTM)
-38.61%
Valuation
Price to revenue (TTM)
2.205
Price to book
6.79
Price to tangible book (TTM)
6.79
Price to free cash flow (TTM)
-55.483
Free cash flow yield (TTM)
-1.80%
Free cash flow per share (TTM)
-0.073
Growth
Revenue change (TTM)
16.77%
Earnings per share change (TTM)
-4.00%
3-year revenue growth (CAGR)
75.89%
3-year earnings per share growth (CAGR)
-7.52%
10-year earnings per share growth (CAGR)
-22.48%
What the Analysts think about Ardelyx
Analyst ratings (Buy, Hold, Sell) for Ardelyx stock.
Ardelyx Financial Performance
Revenues and expenses
Ardelyx Earnings Performance
Company profitability
Ardelyx News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.